ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer
allautoe 0 GECP news
This week, the Annals of Oncology published the “ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer”.
This document results from a virtual consensus building process focused on non-small cell lung cancer (NSCLC) and EGFR gene mutation, organized by the European Society for Medical Oncology (ESMO) and which included 34 experts from 18 countries.
The aim of this work was to develop recommendations on topics that are not covered in detail in the current “ESMO Clinical Practice Guideline” and for which the available evidence is limited or contradictory, such as tissue and biomarker analyses, early and locally advanced disease. , metastatic disease, and clinical trial design, patient perspective and other aspects.
If you are a specialist in the field of thoracic tumors, go to article and learn more about how this consensus-building process unfolded, as well as the recommendations gathered in the article and a summary of the evidence supporting each recommendation.